Eribulin Mesylate

Eribulin Mesylate is a cell cycle specific Anti Cancer drug that belongs to the Class "Non-Taxane microtubule inhibitor".It acts by inhibiting the growth phase of microtubules leading to G2/M cell cylcle blockade, disturption of mitotic spindles and ultimately apoptotic cell death after prolonged mitotic blockade. Eribulin Mesylate is a second choice for metastatic breast cancer that has been previously treated with anthracyclines and taxanes

Brands
Adult Dose
Dose: 0.7 to 1.4 mg/msq
Single Dose: 1 (1.05)
Frequency: As recommended.
Route: I/V
Instructions: Administer the dose on day 1 and day 8 pf 21 day cycle
Neonatal
Paedriatic
Characteristics
. It is of Synthetic origin and belongs to Non taxane microtubule inhibitor. It belongs to monoclonal antibody pharmacological group on the basis of mechanism of action. The Molecular Weight of Eribulin Mesylate is 826.00.
Contraindications
Eribulin Mesylate
Effects
The severe or irreversible adverse effects of Eribulin Mesylate, which give rise to further complications include QT prolongation.Eribulin Mesylate produces potentially life-threatening effects which include Anemia, Neutropenia, Anemia, Peripheral neuropathy. which are responsible for the discontinuation of Eribulin Mesylate therapy.The signs and symptoms that are produced after the acute overdosage of Eribulin Mesylate include Hypersensitivity reactions, Neutropenia.The symptomatic adverse reactions produced by Eribulin Mesylate are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Fatigue, Nausea, Alopecia, Tachycardia, Constipation, Insomnia, Abdominal pain, Dry mouth, Rashes, Stomatitis, Dyspepsia, Depression, Asthenia, Edema, Hot flushes, Rhinitis, Lacrimation, Dry mouth, Alopecia, dizziness, dyspepsia, muscle spasm.
Indications
Eribulin Mesylate is primarily indicated in conditions like Locally advanced or metastatic pancreatic cancer, Metastatic breast cancer.
Interactions
No data regarding the interactions of Eribulin Mesylate was found.
Interfrence
Risks
Drug should not be given to Pregnant Mothers, and Cardiac / Hypertensive Patients.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.
Storage
injection Store at room temperature, .
Warnings
Adjust appropiate doses for neutropenia and peripheral neuropathy. It should not be given in pregnancy and QT prolongation
Back to List

Any information that appears on this website page is provided for the purpose of general information. This website has been compiled in good faith by HMIS.Online. However, no guarantee is made as to the completeness, validity or accuracy of the information it contains.